ProceduresGovernment

Pharmaceutical Products

Code 30 (Harmonized System 2012 by 2 digits)

 2023: US$10B, Total Trade Exchange

2023: US$2.34B, International Sales

  2023: US$7.71B, International Purchases

In 2023, the trade exchange (includes international purchases and sales) of Pharmaceutical Products was US$10B.

In 2023, the states with the most international sales in Pharmaceutical Products were Ciudad de México (US$1.13B), Estado de México (US$350M), Jalisco (US$256M), Morelos (US$233M), and Baja California (US$126M).

The states with the most international purchases in 2023 were Ciudad de México (US$5.77B), Estado de México (US$976M), Jalisco (US$230M), Chihuahua (US$224M), and Baja California (US$185M).

In 2023, the main commercial destinations of Pharmaceutical Products were United States (US$1.01B), Canada (US$193M), Colombia (US$147M), Brazil (US$139M), and Panama (US$116M).

The main commercial origins of Pharmaceutical Products in 2023 were United States (US$1.5B), Germany (US$1.2B), France (US$547M), Switzerland (US$527M), and Ireland (US$464M).

In the global context, the main exporting countries of Pharmaceutical Products in 2022 were Germany (US$123B), United States (US$93.6B), and Ireland (US$86.3B). In the same year, the main importing countries of Pharmaceutical Products were United States (US$163B), Germany (US$77B), and Switzerland (US$48.3B).

Trade Balance of Mexico

#permalink to section

Net Trade Balance

#permalink to section

US$10B, Total Trade Exchange (2023)

In 2023, the total trade exchange of Pharmaceutical Products in Mexico (including international purchases and sales) was US$10B.

The visualizations show the net balance of Pharmaceutical Products at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.

Net International Trade

#permalink to section

July, 2024

  • US$262M, International Sales
  • US$809M, International Purchases

In July 2024, international sales of Pharmaceutical Products were US$262M and a total of US$809M in international purchases. For this month the net trade balance of Pharmaceutical Products it was of -US$548M.

Market Concentration

#permalink to section

2024-Q3: US$230M, International Sales

The visualization shows the quarterly concentration of international sales of Pharmaceutical Products at state level.

In the third quarter of 2024, international sales were US$230M, being the states with the most sales Ciudad de México (US$146M), Jalisco (US$26.4M), and Estado de México (US$22.8M).

Exchange by Territory

#permalink to section

International Sales

#permalink to section

Ciudad de México: US$1.13B, State with the Most International Sales (2023)

United States: US$1.01B, Main commercial destination (2023)

In 2023, the states with the highest international sales in Pharmaceutical Products were Ciudad de México (US$1.13B), Estado de México (US$350M), Jalisco (US$256M), Morelos (US$233M), and Baja California (US$126M).

In 2023, the countries with the most international purchases from Mexico were United States (US$1.01B), Canada (US$193M), Colombia (US$147M), Brazil (US$139M), and Panama (US$116M).

International Purchases

#permalink to section

Ciudad de México: US$5.77B, State with the Most International Purchases (2023)

United States: US$1.5B, Main Commercial Origin (2023)

In 2023, the states with the highest international in Pharmaceutical Products were Ciudad de México (US$5.77B), Estado de México (US$976M), Jalisco (US$230M), Chihuahua (US$224M), and Baja California (US$185M).

The countries with the most international sales to Mexico in 2023 were United States (US$1.5B), Germany (US$1.2B), France (US$547M), Switzerland (US$527M), and Ireland (US$464M).

Specialization

#permalink to section

Specialization by State

#permalink to section

The RCA-Complexity  diagram compares the Revelead Comparative Advantages of states in Pharmaceutical Products  and the Economic Complexity Index of each state.

RCA values ​​greater than 1 indicate that the state has comparative advantages in Pharmaceutical Products. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.

Origins and Trade Destinations

#permalink to section

  • 0.29%, Mexican share in global exports - 2022
  • 0.67%, Mexican share in global imports - 2022

The visualizations show the global market for Pharmaceutical Products. In both charts, Mexico stands out in order to identify its participation in the export and import market.

In 2022, the main exporting countries of Pharmaceutical Products were Germany (US$123B), United States (US$93.6B), and Ireland (US$86.3B). In the same year, the main importing countries for Pharmaceutical Products were United States (US$163B), Germany (US$77B), and Switzerland (US$48.3B).